{"disease":{"id":"epilepsy-focal-seizures-partial-seizures","name":"epilepsy focal seizures partial seizures"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03283371","title":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Biogen","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}